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PENCIRIAN HEMATOLOGI DAN MOLEKULAR HEMOGLOBIN F YANG 
TINGGI DALAM KALANGAN PESAKIT ANEMIA DI HOSPITAL 
UNIVERSITI SAINS MALAYSIA 
ABSTRAK 
 
Anemia adalah satu keadaan yang biasanya dikaitkan dengan pelbagai 
penyakit. Kebiasaannya, tahap hemoglobin F (HbF) dalam orang dewasa kurang 
daripada 1.0%. Terdapat beberapa lokus genetik yang mempunyai pengaruh penting 
terhadap tahap HbF. Tujuan kajian ini adalah untuk menentukan hubungan antara 
tahap HbF yang tinggi dengan parameter hematologi serta kehadiran BCL11A 
(rs1186868) dan HMIP-2 (rs9376090) polimorfisme nukleotida tunggal (SNPs) 
dalam pesakit anemia akibat sebab perolehan. Kajian ini melibatkan 144 pesakit 
anemia dari Hospital Universiti Sains Malaysia (HUSM) yang mempunyai tahap 
HbF > 1.0%. Kromatografi cecair berprestasi tinggi (HPLC) digunakan untuk 
menentukan tahap HbF dan HbA2. Multipleks ARMS-PCR dan gap-PCR masing-
masing telah dilakukan bagi sampel yang mempunyai tahap HbA2 yang tinggi (> 
3.2%) dan tahap HbA2 yang normal (≤3.2%) untuk mengesan mutasi pada kluster 
gen β-globin. Diskriminasi alel untuk rs1186868 dan rs9376090 polimorfisme telah 
dilakukan menggunakan teknik PCR masa nyata untuk sampel yang tidak dapat 
mengesan mutasi pada kluster gen β-globin. Dalam kajian ini, purata umur pesakit 
adalah 19.99 ± 1.64 tahun dan didominasi oleh wanita 61.1%. Majoritinya adalah 
orang Melayu (99.3%). Terdapat korelasi negatif yang sederhana dan signifikan 
secara statistik antara tahap HbF dengan tahap Hb dan bilangan RBC, (r = -0.348, P 
< 0.05) (r = -0.377, P < 0.05). Manakala tahap HbF dengan MCV dan MCH 
menunjukkan korelasi negatif yang lemah tetapi tidak signifikan secara statistik (r = -
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0.079, P > 0.05) (r = -0.073, P > 0.05). Daripada multipleks ARMS-PCR, 65 sampel 
(74.7%) mutasi dikesan dimana 49 adalah heterozigot Cd 26 (75.4%), 10 heterozigot 
Cd 41/42 (15.4%), 3 kompaun heterozigot Cd 26 and Cd 41/42 (4.6%) and 3 
heterozigot IVS 1–1 (4.6%), manakala 22 sampel lagi tidak dapat dikesan. Daripada 
57 sampel, hanya satu sampel (1.8%) dijumpai positif Thai (δβ)°-talasemia jenis 
delesi apabila disaring menggunakan multipleks gap-PCR yang mempunyai empat 
target delesi; Siriraj J Gγ(Aγδβ)o-talasemia, Thai (δβ)°-talasemia, HPFH-6, and Hb 
Lepore. Terdapat perbezaan yang signifikan antara purata tahap HbF pesakit yang 
mempunyai mutasi dan delesi pada kluster gen β-globin dengan yang tidak 
mempunyai mutasi dan deletion pada kluster gen β-globin (P < 0.05). Frekuensi alel 
kecil (MAF) pada kedua-dua rs1186868 dan rs9376090 adalah sama dengan 
penduduk Asia Timur (EAS). Tidak terdapat perbezaan yang signifikan pada tahap 
HbF antara genotip yang mengandungi alel kecil rs9376090 (TC dan CC) jika 
dibandingkan dengan genotip TT (P > 0.05). Sebagai kesimpulan, tahap HbF 
mempunyai korelasi dengan status anemia subjek. Tahap HbF yang tinggi 
menunjukkan hubungan dengan pesakit anemia akibat diwarisi dan sebab perolehan. 
Selain itu, tidak terhadap hubungan antara tahap HbF yang tinggi dengan kehadiran 
SNPs rs9376090-C dalam kalangan pesakit anemia akibat sebab perolehan. 
Meskipun memerlukan penyelidikan yang lebih lanjut dalm bidang ini, kajian ini 
menyediakan data yang boleh digunakan sebagai garis panduan untuk rawatan dan 




HAEMATOLOGICAL AND MOLECULAR CHARACTERISATION OF 
HIGH HAEMOGLOBIN F AMONG ANAEMIC PATIENTS IN HOSPITAL 
UNIVERSITI SAINS MALAYSIA 
ABSTRACT 
 
Anaemia is a condition usually associated with variety of diseases. In normal 
adults, haemoglobin F (HbF) levels are usually less than 1.0%. There are several 
genetic loci that have significant influence on HbF levels. The aim of this study is to 
determine the association between elevated HbF level with haematological 
parameters and the presence of the BCL11A (rs1186868) and HMIP-2 (rs9376090) 
SNPs in anaemic patients due to acquired causes. This study involved 144 anaemic 
patients from Hospital Universiti Sains Malaysia (HUSM) with HbF level > 1.0%. 
High-performance liquid chromatography (HPLC) was used to determine the HbF 
and HbA2 levels. Multiplex ARMS-PCR and gap-PCR were performed for those 
samples with high HbA2 level (>3.2%) and normal HbA2 level (≤3.2%) respectively 
to detect mutation at β-globin gene cluster. Allelic discrimination for rs1186868 and 
rs9376090 were performed using real-time PCR technique for samples with no 
mutation detected. In this study, the mean age of patients is 19.99 ± 1.64 years with 
female 61.1% predominance. Majority were Malays (99.3%). There was a moderate 
negative correlation and statistically significant between HbF level with Hb level and 
RBC count, (r = -0.348, P < 0.05) (r = -0.377, P < 0.05) respectively. Meanwhile, 
the correlation between HbF level with MCV and MCH showed weak negative 
correlation but not statistically significant, (r = -0.079, P > 0.05) (r = -0.073, P > 
0.05) respectively. Following multiplex ARMS-PCR, 65 (74.7%) mutations were 
detected which comprises of 49 heterozygous Cd 26 (75.4%), 10 heterozygous Cd 
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41/42 (15.4%), 3 compound heterozygous Cd 26 and Cd 41/42 (4.6%) and 3 
heterozygous IVS 1–1 (4.6%), while 22 patients were not detected. Out of 57 
samples, only one patient (1.8%) was found positive with Thai (δβ)°-thalassaemia 
type deletions when subjected to the multiplex gap-PCR consisted of four target 
deletions; Siriraj J Gγ(Aγδβ)o-thal, Thai (δβ)°-thalassaemia, HPFH-6, and Hb 
Lepore. There was a significant difference between the mean of HbF level of patients 
with and without β-globin gene cluster mutation and deletion (P < 0.05). The minor 
allele frequency (MAF) in both rs1186868 and rs9376090 shows similar to the East 
Asian (EAS) population. There is no significant difference of HbF level between 
genotypes containing HbF-promoting alleles of rs9376090 (TC and CC) when 
compared to genotype TT (P > 0.05). In conclusion, HbF level correlates with 
anaemic status of the subjects. Elevated HbF levels showed associations with both 
inherited and acquired causes. Additionally, there is no relationship between the 
increased HbF levels with the presence of SNPs rs9376090-C among acquired 
anaemic patients. Despite the need for further research in this area, this study 






1.1 Background of study 
Foetal haemoglobin (HbF) is formed by two α- and two γ-globin chains (α2 
γ2). HbF is synthesised during foetal development due to high expression of γ-globin 
genes (Edoh et al., 2006; Stamatoyannopoulos, 2005). The gamma globin (HBG1 
and HBG2) genes are usually expressed in the liver, spleen, and bone marrow during 
foetal life. The normal switch from HbF to HbA synthesis occurs during the first year 
of life lead to rapidly decreasing of HBF level to reach a concentration of less than 
1% in normal children after the age of 1 year and adults (Pace et al., 2016; Amato et 
al., 2014; Steinberg et al., 2014; Inusa et al., 2006). In normal children and adults, 
the β-globin gene is predominant and γ-globin genes are poorly expressed. 
According to Koh et al. (2017), subjects are considered to have α and β-globin gene 
cluster mutations when the HbF level is more than 1.0%, HbA2 level is above 3.2%, 
and/or show the presence of other abnormal Hb (Koh et al., 2017).  
 
The exact time of disappearance of HbF from red blood cells of infants 
differs and the signal that regulates the switch from HbF to HbA is not known. HbF 
levels can be evaluated by counting the number of F cells, that is, adult erythrocytes 
that contain measurable amounts of HbF (Xu et al., 2009).  
 
Elevated HbF level may have its own clinical consequences. Several acquired 
conditions are associated with increased level of HbF. These include drug-induced 
illness, micronutrient deficiency, and other medical conditions such as aplastic 
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anaemia, pernicious anaemia, sideroblastic anaemia, autoimmune diseases, and 
leukaemia (World Health Organization, 2011). Besides this, a high level of HbF in 
adults is also linked to inherited factors due to mutations or deletions in the beta (β)-
globin gene cluster which cause pathological changes, such as in patients with 
thalassaemia disorders (Sankaran et al., 2008; Thein et al., 2007). The inheritance of 
HbF does not always comply with the Mendelian inheritance pattern; hence, the 
exact underlying cause in the increased level of HbF remains unclear (Sankaran et al., 
2008). 
 
Deletions and/or mutation of various sizes and positions within the β-globin 
gene cluster located on chromosome 11 are responsible for certain clinical disorders, 
namely hereditary persistence of foetal haemoglobin (HPFH), β-thalassaemia, sickle 
cell anaemia, HbE disorder, and delta beta (δβ)-thalassaemia (Carrocini et al., 2011). 
Sickle cell anaemia and β-thalassaemia mutations are characterised by significant 
elevations of HbF and HbA2 levels while HPFH and δβ-thalassaemia mutations are 
characterised by elevations of HbF level but normal HbA2 level (Galanello, 2013). 
 
Furthermore, several genetic loci have a significant influence on HbF level 
(Carrocini et al., 2011). According to Sokolova (2019), the XmnI polymorphism, 
HMIP locus, and BCL11A gene are responsible for 45% of variations in HbF level. It 
has been shown that the variants in BCL11A, HBS1L-MYB and HBB loci are 
associated with HbF levels and ameliorate the severity in β-thalassaemia as well as 
SCA (Gallanello et al., 2009; Lettre et al., 2008). BCL11A, one of the quantitative 
trait loci (QTLs) that control HbF levels, is located in the 2p16 region of 
chromosome 2. Fifteen percent of HbF variations are attributed to BCL11A 
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polymorphisms. BCL11A gene has been established as a direct regulator of HbF level. 
Studies shown that the expression of the transcriptional repressor BCL11A is 
regulated by erythroid-specific enhancers that contain 3′ DNase hypersensitive sites 
(DHS) located +62, + 58, and +55 kb from the transcription initiation site of BCL11A 
(Bauer et al., 2013). Bauer et al. (2013) reported that common genetic variation at 
BCL11A associated with HbF level lies in noncoding sequences decorated by an 
erythroid enhancer chromatin signature. In a study of 179 unrelated healthy subjects 
from a British twin registry, six SNPs in BCL11A which are rs243027, rs243081, 
rs6732518, rs1427407, rs766432 and rs4671393 were reported to be associated with 
F-cell numbers (Menzel et al., 2007).  
 
Another QTL associated with elevated HbF is HBS1L–MYB intergenic 
polymorphism (HMIP) found on chromosome 6 (6q23). It is located between the 
HBS1L gene (codes for elongation factors and regulates multiple cellular processes) 
and the MYB gene (encodes transcription factors and participates in ontogenesis and 
erythropoiesis). HMIP is unique among the HbF modifier loci because it has marked 
pleiotropic effects. For example, it affects general hematological parameters 
including HbF level in healthy individuals (Mtatiro et al., 2015). High-risk genotypes 
of six HbF-associated SNPs, rs9376090, rs7776054, rs9399137, rs9389268, and 
rs9402685 in the HMIP are associated with high HbF level (Lai et al., 2016). 
Previous study in Brazil confirms that common HMIP‐2 variants increase HbF levels 
in SCA patients (Leonardo et al., 2016).  
 
HbF is one of the haematological parameters in evaluating disorders related 
to blood. HbF parameter is considered as a potential biomarker that indicates the 
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presence of underlying diseases; however, this requires further investigation 
(Steinberg et al., 2009). HbF has shown a great importance where it improved the 
clinical features of an individual with sickle cell disease and β-thalassaemia 
(Steinberg and Thein, 2018). This nonspecific biomarker is important, denoting a 
pathophysiological process in patients with silent or non-straight forward disorders 
which can be associated particularly with anaemic conditions (Steinberg et al., 2009). 
 
1.2 Significance of the study  
A number of SNPs have been shown specifically to be beneficial in 
ameliorating the severity of anaemia due to inherited causes by influencing the levels 
of adult HbF. To date, the data regarding the role of HbF associated with acquired 
anaemia among Malaysian population are still lacking. Mapping of QTLs as 
proposed in this study is one of the tools to identify the susceptible SNPs specifically 
BCL11A and HMIP-2 and determine its association with elevated HbF in acquired 
anaemia patients. Thus, the benefit of this study is imperative in considering the role 
of genetics (SNPs) in BCL11A and HMIP-2 as a potential disease biomarker for HbF 
in anaemia severity and could provide better approach in management of anemic 
patients.  
 
1.3 Objective of the study 
1.3.1 General objective 
To study the role of HbF as a potential disease biomarker among anaemic patients 
with increased HbF level due to acquired causes. 
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1.3.2 Specific objectives 
1. To study the association between HbF level and anaemic status of the 
subjects. 
2. To determine the increased of HbF levels in anaemic patients due to inherited 
or acquired causes. 
3. To determine the association between elevated HbF and the presence of SNPs 
rsll86868 dan rs9376090 in anaemic patients due to acquired causes. 
 
1.4 Hypotheses of the study 
1. There is a correlation between HbF level and anaemic status of the subjects. 
2. There is an association between HbF level due to inherited causes and 
acquired causes. 
3. There is an association between high HbF with SNPs rs1186868 and 





2.1 Haemoglobin  
Erythrocytes contain a protein known as haemoglobin (Hb) that carries 
oxygen from the lungs to all parts of the body. The biconcave shape of erythrocytes 
allows high diffusion rate of oxygen and carbon dioxide across their membrane 
(Diez-Silva et al., 2010). Hb is a complex protein made up of two pairs of 
homologous subunits, alpha (α) and beta (β). Each Hb molecule forms a pocket 
containing a haem group, which has an important role in oxygen-binding capacity 
(Farashi and Harteveld, 2017). In the arterial circulation, Hb encompasses a high 
affinity for oxygen and a low affinity for carbon dioxide, organic phosphates, and 
hydrogen and chloride ions. In the venous circulation, these relative affinities are 
vice versa (Marengo, 2006). There are seven types of Hb throughout human life. The 
list of Hb types is shown in Table 2.1. 
 
Each type of Hb comprises different compositions of globin chains. Adult 
haemoglobin (HbA) is a predominant type of Hb which starts to develop after three 
months of postnatal life. HbA consists of two alpha chains and two beta chains (α2 
β2) (Figure 2.1) (Campbell, 2009). HbA is the major component of Hb in normal 
adults, usually comprising about 97% of the total Hb. The remainder is HbA2 (α2 δ2) 





Figure 2.1 Types of haemoglobin. Adapted from Manning et al., 2007. 
  
During the foetal stage, HbF is the predominant type of Hb. Hb switching 
refers to the developmental process that leads to the silencing of gamma (γ)-globin 
gene expression and the reciprocal activation of adult beta (β)-globin gene expression 
(Frenette and Atweh, 2007). 
 
Table 2.1 The types of haemoglobin in humans  
Haemoglobin Subunit/structure Classification 
A α2β2 Adult 
HbA2 α2δ2 Adult 
F α2γ2 Foetal 
Gower I ζ2ε2 Embryonic 
Gower II α2ε2 Embryonic 
Portland I ζ2γ2 Embryonic 
Portland II ζ2β2 Embryonic 
Adapted from Manning et al., 2007. 
 
2.1.1 Foetal Haemoglobin (HbF) 
Foetal haemoglobin (HbF) is formed by two α- and two γ-globin chains 
(α2 γ2) (Stamatoyannopoulos, 2005). The oxygen affinity for HbF increase because 
the absent of 2,3-bisphosphoglycerate (2,3-DPG). 2,3-DPG is a little molecule in the 
erythrocytes that binds with haemoglobin beta subunits and it decreases the affinity 
for oxygen and promotes the release of the remaining oxygen molecules bound to the 
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haemoglobin. The high affinity of HbF for oxygen favors the taking up of oxygen in 
the placenta. HbF is important in transporting oxygen from maternal to foetal 
circulation. The HbF oxygen dissociation curve is left-shifted in comparison to HbA. 
The partial pressure at which HbF is half saturated with oxygen (P50) is 19 mm Hg, 
compared to 27 mm Hg for HbA. This value indicates that HbF has a high affinity 
for oxygen, giving HbF the ability to bind oxygen more readily from the maternal 
circulation. In the foetal systemic circulation, the low oxygen tension allows for 
proper unloading of oxygen, despite HbF's oxygen affinity. The lower oxygen 
tension in the foetus is important for development, particularly in angiogenesis. 
Because foetal blood shows a higher affinity for oxygen than maternal blood, oxygen 
will diffuse from the pregnant maternal to the foetal circulation within the placenta, 
allowing for oxygenation of foetal tissues. 
 
In adults, the β-globin gene is predominant; approximately 98% of all Hb 
consist of HbA (α2 β2). Thus, γ-globin genes are poorly expressed; less than 1% of 
Hb in adults is made up of HbF (Xu et al., 2009). HbF levels can be evaluated by 
counting the number of F cells. The HbF and F-cell levels vary considerably in 
healthy adults, but commonly, there is a good correlation between the two (Menzel et 
al., 2007). The concentration of HbF depends on several factors. HbF is increased in 
inherited conditions, such as HPFH, hereditary spherocytosis, sickle cell crisis, and 
thalassaemia. The level of HbF is also elevated in acquired states, such as pregnancy, 
aplastic anaemia, thyrotoxicosis, hepatoma, myeloproliferative disorders, and 
hypoplastic myelodysplastic syndrome. In addition, several genetic loci may also 
significantly influence HbF level (Carrocini et al., 2011).  
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Certain mutations within the β-globin gene cluster are associated with 
increased γ-chain expression (Cao and Galanello, 2010). For example, in β-
thalassaemia and related conditions, gamma chain production continues into 
adulthood for additional γ-globin chains to bind with the excess of α-chains and 
causes imbalance between α and β-globin chains. Thus, HbF is synthesized to help 
the erythrocytes survive longer in the circulation. Therefore, induction of HbF 
expression in erythroid cells is an important therapeutic approach in patients with Hb 
disease (Fathallah and Atweh, 2006). Patients with HbF levels of ≥20% have a mild 
phenotype and those with levels of ≥30% are likely to be asymptomatic (Adekile, 
2011). 
 
2.2 Anaemia  
Anaemia is a global public health problem that affects both developing and 
developed countries. Anaemia is generally classified based on blood loss, lower 
erythrocytes production or ineffective erythropoiesis and haemolysis of erythrocytes. 
More specifically, anaemia is defined as the condition where the normal level of Hb 
is lower in the body, which reduces the oxygen-carrying capacity (Henry et al., 
2004). The World Health Organization (WHO) defines anaemia by a level of Hb less 
than 13.0, 12.0, and 11.0 g/dL in men, non-pregnant women, and pregnant women, 
respectively (Table 2.2). Meanwhile, severe anaemia is defined as Hb <7.0 g/dL in 
children aged 6 to 59 months and pregnant woman while Hb <8.0 g/dL in others. 
According to WHO, anaemia exists in the following proportions: 3.9% of men, 
38.5% of pregnant women, and 17.3% of non-pregnant women. The Western 
countries have an increased occurrence of anaemia in the elderly population (Gaskell 
et al., 2008). 
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Table 2.2 Haemoglobin levels in different age groups (g/dL) 
Population Non-anaemia Mild Moderate Severe 
Children 6 - 59 
months of age 
> 11.0 10.0-10.9 7.0-9.9 < 7.0 
Children 5 - 11 
years of age 
> 11.5 11.0-11.4 8.0-10.9 < 8.0 
Children 12 - 14 
years of age 
> 12.0 11.0-11.9 8.0-10.9 < 8.0 
Non-pregnant 
women (15 years 
of age and above) 
> 12.0 11.0-11.9 8.0-10.9 < 8.0 
Pregnant women > 11.0 10.0-10.9 7.0-9.9 < 7.0 
Men (15 years of 
age and above) 
> 13.0 11.0-12.9 8.0-10.9 < 8.0 
Adapted from World Health Organization, 2011. 
 
Normal Hb distribution varies in different genders and ethnicities as well as 
the physiological statuses of an individual. The patient’s history and physical 
examination should be taken into consideration when performing anaemia diagnosis 
(Conrad, 1990). Several factors affect the concentration of Hb which can be divided 
into inherited and acquired causes. Examples of inherited disorders are congenital 
pernicious anaemia, Fanconi anaemia, G6PD deficiency, hereditary spherocytosis, 
thalassaemia and its variants such as sickle cell anaemia (Mosca et al., 2009; Bain, 
2006). Thalassaemia may be treated with blood transfusions as well as other 
treatments such as iron chelation therapy and folic acid consumption because of the 
reduced production of healthy erythrocytes and Hb. Sickle cell anaemia is the 
production of abnormal form of Hb that causes erythrocytes to change from a 
biconcave to a sickle shape. This abnormal shape of erythrocytes causes them to 
stick together, resulting in difficulty for them to pass through blood vessels, leading 
to damage of the body tissues (Jones, 2017). 
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Meanwhile, acquired conditions of anaemia can be drug-induced anaemia, 
aplastic anaemia, pernicious anaemia, sideroblastic anaemia, vitamin B12/folate 
deficiency, autoimmune diseases (a form of anaemia of chronic disease), and 
leukaemia as well as physiological characteristics such as age, pregnancy status, and 
sex (Mosca et al., 2009). In some cases, certain drugs can cause the immune system 
to attack the body's own erythrocytes by producing antibodies. These antibodies 
attach to erythrocytes and cause haemolysis. Examples of drugs that can cause this 
type of haemolytic anaemia include cephalosporin, a class of antibiotics (Garratty, 
2009). Cephalosporin is an example of drug-dependent antibodies causing 
production of erythrocyte autoantibodies which affect the immune system. Drugs 
bind covalently to erythrocyte membrane proteins. Drug antibodies, usually IgG, 
attach themselves to drug-coated erythrocytes and are subsequently cleared by 
macrophages (Garratty, 2012). Frequent adverse drug reactions (ADRs) (≥1.0% of 
patients) associated with cephalosporin therapy include diarrhoea, nausea, skin 
rashes, electrolyte disturbances, and inflammation at the injection site. Uncommon 
ADRs (0.1%–1.0% of patients) include headache, dizziness, vomiting, oral and 
vaginal candidiasis, nephrotoxicity, pseudomembranous colitis, eosinophilia, 
superinfection, neutropenia, thrombocytopenia, and fever (Shi et al., 2013). 
 
Heavy menstruation, ulcers, injury, or surgery cause blood loss leading to 
iron-deficiency anaemia. Pregnancy also causes changes in a woman's blood volume 
which can result in anaemia. Contributions of each of the factors that causes anaemia 
during pregnancy vary due to geographical location, dietary practice, and season 
(Stephen et al., 2018). A diet low in iron, folate, or vitamin B12 increases the risk of 
iron-deficiency anaemia. These nutrients are important in growth and development 
12 
(Song et al., 2010). Folate, vitamin B12, and iron have crucial roles in erythropoiesis. 
Erythroblasts require folate and vitamin B12 for proliferation during their 
differentiation. Deficiency of folate or vitamin B12 inhibits purine and thymidylate 
syntheses, impairs DNA synthesis, and causes erythroblast apoptosis, resulting in 
anaemia from ineffective erythropoiesis (Koury and Ponka, 2004). In addition, 
anaemia is caused by parasitic infections such as malaria and hookworm or chronic 
infections like tuberculosis (TB) and human immunodeficiency virus (HIV) (Ononge 
et al., 2014). People with chronic diseases have the greatest risk of anaemia. Chronic 
diseases such as kidney disease can affect the body's ability to make erythrocytes. 
Patients with anaemia of chronic disease have mild to moderate anaemia that tends to 
correlate in severity with the underlying disease (Smith, 2000). 
 
2.3 Inherited anaemic conditions associated with elevated HbF: Beta (β)-
globin gene cluster mutation 
The β-globin gene cluster locus is located at chromosome 11, which is 
composed of epsilon (ε), G-gamma (Gγ), A-gamma (Aγ), delta (δ), and β-globin 
genes as shown in Figure 2.2. Expression of the β-globin gene cluster locus is 
controlled by a single locus control region (LCR), the most important regulatory 
element in the locus, which is located upstream of the globin gene (Frenette and 
Atweh, 2007). Majority of the β-globin alterations are due to point mutations. To 
date, numerous mutations affect the β-globin gene cluster with most cases being 
single nucleotide substitutions, insertions, or short deletions (Thein, 2011). Examples 
of mutations associated with the β-globin gene cluster are HPFH, δβ-thalassaemia, 
and β-thalassaemia and its variants.  
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Figure 2.2 The β-globin gene consists of five functional genes (blue boxes) and two 
pseudogenes (diagonal lines). Adapted from Lodish et al., 2000.  
 
2.3.1 β-globin genes cluster mutation  
In a routine clinical setting, HbA2 level of more than 4.0% indicates β-
thalassaemia or severe β-thalassaemia while in mild β-thalassaemia, HbA2 level is 
usually more than 3.6% (Ministry of Health, 2009). Fucharoen et al. (2002) observed 
that HPFH-6 and δβ-thalassaemia Thai patients have high HbF (>5%) and normal 
HbA2 (2.2%) levels. However, Koh et al. (2017), reported that subjects are 
considered to have α and β-globin gene cluster mutations when the HbF level is more 
than 1.0%, HbA2 level is above 3.2%, and/or show the presence of other abnormal 
Hb. Therefore, in this study, samples with high HbF level (>1.0%) and HbA2 level 
(>3.2%) were chosen for detection of β-globin gene cluster mutation while samples 
with high HbF level (>1.0%) and normal HbA2 level (≤3.2%) were used for detection 
of β-globin gene cluster deletion. 
 
β-thalassaemia and its variants are the examples of β-globin gene cluster 
mutation. β-thalassaemia is a heterogenous group of autosomal recessive disorders 
that cause a genetically deficient synthesis of β-globin chain in Hb (Thein, 2011). β-
thalassaemia phenotype can also arise from structural β-globin chain variants. The 
common β-globin chain variants are haemoglobin C (HbC), haemoglobin S (HbS or 
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sickle cell), and haemoglobin E (HbE), while others are rare (Weatherall, 2001). 
Entries in the database of human Hb variants and thalassaemia mutations (HbVar) 
show that, at present, at least 228 entries are associated with the deletion mutation. β-
thalassaemia is an inherited blood disorder that leads to ineffective erythropoiesis. 
Genetically, β-thalassaemia can be inherited from parents to a child and can be 
classified into three groups which are β-thalassaemia minor, β-thalassaemia 
intermedia, and β-thalassaemia major (Table 2.3). 
 
Table 2.3 The classifications of β-thalassaemia  
Classification Genotype 
β-thalassaemia minor β/β+, β/β° 
β-thalassaemia intermedia β+/β+, β+/β° 
β-thalassaemia major β°/β° 
Adapted from George, 2013. Abbreviations: (β): presence of β-globin chain synthesis; (βo): 
absence of β-globin chain synthesis; (β+): reduction of β-globin chain synthesis.  
 
Between 1.5% and 7.0% of the world population are estimated to carry one of 
the genes that cause β-thalassaemia (Roth et al., 2018). More than 800 mutation 
entries involving β-globin gene are recorded in the database of Hb variants and 
thalassaemia mutations (HbVar, 2013). Malaysia is a multi-ethnic country consisting 
of three major ethnic groups (Malays, Chinese, and Indians) and other minor ethnic 
groups, which include Orang Asli (Department of Statistics Malaysia, 2018). It was 
reported that 4.5% of the Malaysian population are carriers for β-thalassaemia, where 
it is commonly found among Malays and Chinese (George et al., 2001), but rare in 
Indian ethnic (Tan et al., 2006). 
 
Each ethnic group in Malaysia possesses its own specific set of mutations 
(Tan et al., 2006). According to Tan et al. (2004), β-thalassaemia with a structural 
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Hb variant, HbE is usually found among the Malays by 76.0%. Another study 
showed that Cd 26 (G–A) or HbE is the most observed β-globin mutation by 84.8% 
in transfusion-dependent β-thalassaemia Malay patients in Kelantan (Hanafi et al., 
2014). This is somehow anticipated since Kelantan geographically shares its border 
with the Narathiwat Province of Thailand. The prevalence of HbE carriers among 
Thais is from 10.0% to 60.0% depending on the region and the lowest prevalence 
rate of thalassaemia and HbE was in the Southern Thailand region (Nuinoon et al., 
2014). Furthermore, interracial marriages between the Southern Thais and 
Kelantanese are common and they have been crisscrossing the border since a long 
time ago. Indeed, the β-chain mutations among the Kelantanese population are 
almost equivalent to those in Southern Thailand (Hanafi et al., 2014). 
 
HbE is the most common Hb variant that occurs in Southeast Asia. HbE is a 
type of structural defect that is caused by a point mutation of the β-globin gene. It is 
caused by a base substitution at codon 26 of the β-globin gene, GAG–AAG, which 
results in the substitution of lysine for glutamic acid (Fucharoen and Weatherall, 
2012). HbE can be characterised as HbE trait (heterozygous), HbE disease 
(homozygous), and a variety of compound heterozygous states such as HbE/β-
thalassaemia and HbE/sickle cell disease (Bachir and Galacteros, 2004). When β-
thalassaemia is co-inherited with HbE (HbE/β°-thalassaemia), these individuals may 
have severe anaemia and require frequent blood transfusions (Wahed and Dasgupta, 
2015). HbE occurs at high frequency in many countries in Asia. HbE is widely 
distributed in Bangladesh, East India, Southeast Asia, and with high prevalence in 
the borders of Thailand, Laos, and Cambodia, in which these countries are known as 
the ‘HbE triangle’. In these areas, its prevalence can reach up to 50%–60%. In 
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Malaysia, HbE is common among Malays with a carrier rate of 5%. Moreover, HbE 
has also been identified to be high among the Orang Asli in Peninsular Malaysia 
(George, 2013). This is supported by a study conducted on Senoi group of Orang 
Asli, where HbE is the most common mutation with a rate of 18.6% (Koh et al., 
2017). Globally, individuals with HbE/β-thalassaemia compose almost 50% of those 
affected with thalassaemia (Olivieri et al., 2011). 
 
2.3.2 β-globin genes cluster deletion 
According to Galanello (2013), deletions affecting the β-globin gene cluster 
result in the removal of the δ and/or β genes but leave one or both γ genes intact. 
This leads to the occurrence of β-thalassaemia, HPFH, δβ-thalassaemia, Hb Lepore, 
and γδβ-thalassaemia. Deletions that remove all or part of the β-globin gene are 
classified as β-thalassaemia deletions. Meanwhile, deletions that remove the δ- and 
β-globin genes are termed δβ-thalassaemia, and this is often associated with 
moderate increases in HbF. This deletion causes the expression of both γ-globin 
genes at high level to compensate for the absence of β-globin production. The 
clinical symptoms of δβ-thalassaemia heterozygous have similar presentations to 
thalassaemia minor with hypochromic microcytic red cells but normal levels of 
HbA2. Homozygotes for δβ-thalassaemia or compound heterozygotes with β-
thalassaemia are not common but have been reported to have clinical phenotypes 
ranging from mild anaemia to thalassaemia major (Thein, 2011). 
 
γδβ-Thalassaemia is characterised by a heterogeneous array of large deletions 
of the β-globin gene complex of sizes ~100 kb or greater, which include all parts of 
the β-globin gene complex (Sabath, 2017). These deletions prevent the 
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transcriptional activation of any of the cis-linked β-globin genes at any 
developmental stage (Bender et al., 2000). Driscoll et al. (1989), reported a case of a 
patient with γδβ-thalassaemia affected by a de novo deletion on the β-globin gene 
chromosome involving ~30 kb of sequences. This deletion extends from 9.5 to 39 kb 
of the ε-globin gene. γδβ-thalassaemia is lethal in the homozygous state. However, in 
the heterozygous state, the disease is transient while manifesting as moderately 
severe microcytic anaemia in newborns (Thein, 2011). 
 
Meanwhile, HPFH involves large deletions that remove the adult δ and β 
genes but leave the paired foetal genes (G gamma and A gamma) intact (Collins et 
al., 1987). Incomplete or failed switching of the HbF to HbA causes a high level of 
HbF expression in adults (Galanello, 2013). This results in the expression of cis-
linked foetal globin genes in adult erythroid cells which leads to higher HbF level in 
adult life (Bank, 2006). HPFH is commonly seen in the African population (Ngo et 
al., 2012). These deletions result in elevated HbF level that is significantly higher 
than that observed in β- or δβ-thalassaemia. HPFH heterozygotes have normal red 
blood cell indices but higher HbF compared to δβ-thalassaemia patients (Rochette et 
al., 1994). Individuals with HPFH heterozygotes are asymptomatic (Patel et al., 
2015). HPFH homozygotes are clinically normal, and their Hb level may be 
increased with mildly hypochromic microcytic red cells (Thein, 2011).  
 
Hence, HPFH and δβ-thalassaemia are characterised by the persistent 
expression of γ-globin genes in adults, and also the presence of the hypochromic and 
microcytic erythrocytes (Weatherall, 2001). Homozygotes for δβ-thalassaemia as 
well as compound heterozygotes for δβ-thalassaemia with β-thalassaemia usually 
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lead to a clinical phenotype of thalassaemia intermedia or major. Although HPFH 
homozygotes are clinically asymptomatic, compound heterozygotes for HPFH with 
β-thalassaemia express similar phenotype as in those with thalassaemia intermedia 
(Panyasai et al., 2004). Individuals with HPFH/β-thalassaemia may have mild 
anaemia but are clinically asymptomatic (Thein, 2011). 
 
Another type of deletion for β-globin gene cluster is caused by unequal 
crossover between the linked and partially homologous δ- and β-globin genes, 
leading to the development of a fusion of δβ-globin gene, also known as the Hb 
Lepore. Hb Lepore may be easily detected by the electrophoretic method. It 
constitutes 6% to 15% of the total Hb, with HbA2 level being normal or discreetly 
reduced. The haematological profiles from all these variants show a moderate 
increase of the HbF levels ranging between 2% and 4% while a combination of Hb 
Lepore and HbA2 has been observed at the range of 10% to 13% (Guo et al., 2015). 
 
In Asia, approximately 12 types of deletion in the β-globin gene cluster have 
been defined within the Southeast Asian populations. This includes the β°-
thalassaemia 105 bp deletion, the 619 bp deletion, the 3.5 kb deletion, the novel 
Gγ(Aγδβ)°-thalassaemia, Siriraj J deletion (~118 kb deletion), the Southeast Asian 
(SEA) deletion (~27 kb deletion), the Filipino deletion (~45 kb deletion), Hb Lepore 
(~7.4 kb deletion), the Thai (δβ)°-thalassaemia deletion (~12.5 kb deletion), the 
Chinese Gγ(Aγδβ)°-thalassaemia (~100 kb deletion), and the Asian Indian deletion–
inversion Gγ(Aγδβ)°-thalassaemia, as well as HPFH-6 and Vietnamese HPFH 
(known as HPFH-7 in HbVar) deletions (Tritipsombut et al., 2012). In Asian Indian 
β-thalassaemia patients, almost 30% of the chromosomes have a 619 bp deletion. 
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This mutation affects the 3ʹ end of the large IVS II, the entire exon 3, and a short 
section of DNA 3ʹ to the β-globin gene (Thein et al., 2009). 
 
2.4 Acquired anaemic conditions associated with elevated HbF 
Several acquired conditions are associated with elevated HbF. These include 
drug-induced anaemia, aplastic anaemia, pernicious anaemia, sideroblastic anaemia, 
vitamin B12/folate deficiency, autoimmune diseases, and leukaemia (Mosca et al., 
2009). Anaemia in pregnancy is classified into two, which are pathological anaemia 
and physiological anaemia. Pathological anaemia is further subclassified into 
haemorrhagic and deficiency anaemia such as vitamin B12 deficiency, iron 
deficiency, protein deficiency, and folic acid deficiency. Meanwhile, physiological 
anaemia is due to the joint effect of haemodilution and negative iron balance. Iron 
deficiency secondary is the main factor of anaemia in pregnant women because of 
chronic menstruation and inadequate dietary intake (Sabina et al., 2015). 
 
According to the National Organization for Rare Disorders (NORD, 2004), 
rare disorders such as autoimmune haemolytic anaemia is one of the acquired 
anaemia. It is characterised by the premature destruction (haemolysis) of 
erythrocytes. Acquired autoimmune diseases occur when the body's natural defences 
such as lymphocytes and antibodies destroy its own healthy tissues. Acquired 
autoimmune haemolytic anaemia is a disorder that occurs in individuals who 
previously had a normal red blood cell system.  
 
Chemotherapy, radiation, and some drugs used to treat leukaemia may cause 
aplastic anaemia because some cancer therapies prevent the bone marrow from 
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synthesising new, healthy blood cells. Leukocyte count is lowered first, followed by 
platelet count and erythrocyte count. Anaemia due to cancer treatments may be 
reversible after the treatment is completed (Deborah et al., 2016). Leukaemia itself 
can also cause anaemia. In leukaemia, leukocytes multiply rapidly, resulting in 
difficulty for erythrocytes to develop. Other than that, cancer treatments may cause 
decreased appetite, nausea, and vomiting. This often makes it difficult for patients to 
eat a nutritious, iron-rich diet, and thus may lead to iron-deficiency anaemia 
(Weatherspoon, 2016). 
 
2.5 Single nucleotide polymorphisms (SNPs) associated with high foetal 
haemoglobin (HbF)  
Single nucleotide polymorphisms (SNPs) occur when a single nucleotide base 
pair is substituted after the body makes new cells. SNPs are responsible for the 
diversity among individuals, genome evolution, interindividual differences in drug 
response as well as complex and common disease such as diabetes, obesity, 
hypertension, and psychiatric disorders. SNPs are the most common type of genetic 
variation among people. The significance of the variants may change the downstream 
outcomes. In cells, the variant may influence promoter activity (gene expression), 
messenger RNA (mRNA) stability, and subcellular localisation of mRNAs and/or 
proteins and hence, may produce the disease (Shastry, 2009). Quantitative trait loci 
(QTLs) are regions of DNA which are associated with a particular phenotype 
attributed to polygenic effects such as the product of two or more genes and their 
environment. QTLs are mapped by identifying the correlation of SNPs with an 
observed trait (Grisel and Crabbe, 1995).  
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SNPs can be used as a predictive marker for diseases. SNPs are associated 
with cancerous or non-cancerous diseases as well as anaemia. Therefore, SNPs offer 
valuable markers for identifying genes responsible for susceptibility to common 
diseases (Nassiri et al., 2013). Some genome-wide association studies have reported 
that there are at least three major loci that play a major role in increased HbF level 
(Rujito et al., 2016). Previous studies have shown that SNPs in certain QTLs are 
actively associated with the range of HbF in anaemia as shown in Table 2.4. 
 
Table 2.4  Example of QTLs that are associated with HbF level 
Gene Location Variant 
BCL11A 2p16 rs1186868 
rs1427407 
rs7557939 








HBG2-Xmn1 11p15 rs7482144 
Adapted from Uda et al., 2018; Lai et al., 2016; Fong et al., 2015; Sheehan, 2013.  
 
The QTL associated with elevated HbF is BCL11A, located in the 2p16 region 
of chromosome 2. The percentage of HbF variations attributed to BCL11A QTLs is 
15%. BCL11A is more frequent in patients with β-thalassaemia intermedia than in β-
thalassaemia major (Sokolova, 2019). There is a strong association between genetic 
variants in the BCL11A gene and HbF levels in numerous populations (Sankaran et 
al., 2008). BCL11A gene has been suggested as a direct regulator of HbF level 
(Basak and Sankaran 2016). A SNP in BCL11A was associated with HbF level in 
Sardinians with β-thalassaemia and in African Americans with sickle cell disease 
(Uda et al., 2008). Two SNPs in BCL11A genes are associated with increasing HbF 
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levels in patients with HbE/β-thal patients in Indonesian population (Rujito et al., 
2016). 
 
Polymorphisms associated with F-cell level in an intergenic region between 
the genes HBS1L and MYB, also known as HMIP, have been identified (Thein et al., 
2007). A previous study showed that there is an association signal of HbF level in the 
HBS1L–MYB intergenic region in a large non-anaemic Sardinian cohort (Menzel et 
al., 2007). The HBS1L–MYB is located on chromosome 6 between the HBS1L gene 
(codes for elongation factors and regulates multiple cellular processes) and the MYB 
gene (encodes transcription factors and participates in ontogenesis and 
erythropoiesis). This QTL codes for factors that participate in the erythroid 
maturation pathway. Wahlberg et al. (2009), showed a correlation between 6q23 
QTL and HbF level in Indian β-thalassaemia patients. It is yet to be determined 
whether this correlation is secondary to a direct or indirect effect. Craig et al. (1996), 
studied Indian female population with β-thalassaemia and found that those with 
homozygous 6q23 QTL have a higher HbF concentration (24% compared to 10%). 
The same correlation was noticed among the healthy population in this study (3%–
1%). 
 
The QTL on chromosome 8, 8q region is suggested to influence HbF levels 
by encoding transcriptional factors, which bind to the XmnI site. The SNP rs7482144 
at 158 bp 5' of HBG2 gene on chromosome 11p15.4 is associated with elevated HbF 
in thalassaemia and sickle cell disease (Gilman and Huisman, 1985). QTLs for HbF 
level have been defined on chromosomes 6q23, 8q, and Xp22 (Thein et al., 2007). 
The biological effect of the QTLs on HbF expression includes two plausible 
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mechanisms. First, the direct effect on HBG gene transcription activation or 
repression which increases or decreases the amount of HbF. Second, the alteration of 
the kinetics of erythroid maturation and differentiation, mimicking a situation 
encountered in stress erythropoiesis, resulting in accelerated erythropoiesis with the 
release of more erythroid progenitors that synthesise predominantly HbF level (Thein 
et al., 2009).  
 
2.5.1 Methods for single nucleotide polymorphisms (SNPs) genotyping 
Single nucleotide polymorphisms (SNPs) are common DNA sequence 
variations that occur at single bases within a genome. The increase of interest in 
SNPs is reflected by the furious development of SNPs genotyping methods including 
array-based hybridisation, allele specific PCR, restriction fragment length 
polymorphism (RFLP) techniques as well as sequencing. PCR allelic discrimination 
technologies have broad applications in the detection of SNPs in genetics and 
genomics. Two different PCR-based allelic discrimination techniques, namely 
Custom TaqMan SNPs genotyping and high-resolution melting (HRM) assays, have 
been developed. The allelic specificity of TaqMan assay is provided by two probes, 
one labelled with FAM dye and the other with VIC dye (Kamau et al., 2012). 
 
Ghomi et al. (2014), reported that TaqMan assays have proven to be more 
sensitive and more reliable than HRM assays. Moreover, the TaqMan SNPs assays 
have been further improved by developing a rapid and straighforward protocol that 
includes crude leaf extraction for RNA template preparations. For a project involving 
a small number of SNPs and a large population, the TaqMan assay is the preferred 
24 
technology as it has high throughput and is highly accurate, precise, time efficient, 
and cost effective (Shen et al., 2009). 
 
One of the most efficient ways to analyse genotypes is through the TaqMan 
allelic discrimination, which has frequently been used to characterise SNPs. TaqMan 
SNPs genotyping assays use 5′ nuclease assay chemistry to detect specific SNPs, 
multinucleotide polymorphism and insertion or deletion alleles (Gaedigk et al., 
2015). A relatively small region flanking the target single nucleotide variant is 
amplified using locus-specific primers and alleles are detected using two TaqMan 
probes with conjugated minor groove binder (MGB) labelled with VIC dye or FAM 
dye (Kamau et al., 2012). 
 
2.6 Haematological analysis  
Hb level, mean corpuscular volume (MCV), and mean corpuscular 
haemoglobin (MCH) are the parameters used as a guideline for the first-line 
screening of anaemia (Alquaiz et al., 2012). A patient who possesses red cell indices 
are below the normal range is considered to have anaemia as shown in Table 2.5. 
 
Table 2.5  Age and gender related red cell indices for children and adults under 
normal condition 
  Hb (g/dL) MCV (fL) MCH (pg) 
Male 1-12  120-135 79.0-84.0 27.4-28.7 
 12-18 130-160 85.0-87.0 29.1-29.9 
 18 and above 130-160 89.0-97.0 30.5-37.8 
Female 1-12 120-135 79.0-84.0 27.4-28.7 
 12-18 120-160 86.0-88.0 29.4-30.0 
 18 and above 120-150 90.0-95.6 30.6-32.6 
Adapted from Yip et al., 1984. Abbreviations: Based on the US second National Health and 
Nutrition Examination Survey (NHANES II) after excluding those with abnormal tests 
related to iron. 
 
